## Where We Are Now with LEN for PrEP



Gilead submits new drug application to U.S. Food and Drug Administration for twice-yearly lenacapavir for HIV prevention EUROPEAN MEDICINES AGENCY

Gilead submits marketing authorization application to the European Medicines Agency



European Medicines Agency agrees to accelerated review of LEN for PrEP Organization
WHO guidelines and

WHO guidelines and initial regulatory approvals are expected around the time of IAS in Kigali PEPFAR and Global Fund can procure after regulatory approvals and WHO recommendation

